Cost Sharing, Family Health Care Burden, and the Use of Specialty Drugs for Rheumatoid Arthritis

Authors

  • Pinar Karaca-Mandic,

    1. University of Minnesota, 420 Deleware Street SE, MMC729, Minneapolis, MN 55455
    Search for more papers by this author
    • Address correspondence to Pinar Karaca-Mandic, Ph.D., Assistant Professor, Division of Health Policy and Management, School of Public Health, University of Minnesota, 420 Deleware Street SE, MMC729, Minneapolis, MN 55455; e-mail: pkmandic@umn.edu. Geoffrey F. Joyce, Ph.D., Associate Professor, is with the Clinical Pharmacy and Pharmaceutical Economics & Policy, School of Pharmacy, University of Southern California, Los Angeles, CA. Dana P. Goldman, Ph.D., Professor, is with Norman Topping/National Medical Enterprises, University of Southern California, Los Angeles, CA. Dana P. Goldman, Ph.D., Chair, is also with Medicine and Public Policy, University of Southern California, Los Angeles, CA. Dana P. Goldman, Ph.D., Director, is also with Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA. Marianne Laouri, Ph.D., Director, Health Economics & Outcomes, is with Quorum Consulting, San Francisco, CA.

  • Geoffrey F. Joyce,

    1. University of Southern California, Los Angeles, CA
    Search for more papers by this author
  • Dana P. Goldman,

    1. University of Southern California, Los Angeles, CA
    Search for more papers by this author
  • Marianne Laouri

    1. Quorum Consulting, San Francisco, CA.
    Search for more papers by this author

Abstract

Objectives. To examine the impact of benefit generosity and household health care financial burden on the demand for specialty drugs in the treatment of rheumatoid arthritis (RA).

Data Sources/Study Setting. Enrollment, claims, and benefit design information for 35 large private employers during 2000–2005.

Study Design. We estimated multivariate models of the effects of benefit generosity and household financial burden on initiation and continuation of biologic therapies.

Data Extraction Methods. We defined initiation of biologic therapy as first-time use of etanercept, adalimumab, or infliximab, and we constructed an index of plan generosity based on coverage of biologic therapies in each plan. We estimated the household's burden by summing up the annual out-of-pocket (OOP) expenses of other family members.

Principal Findings. Benefit generosity affected both the likelihood of initiating a biologic and continuing drug therapy, although the effects were stronger for initiation. Initiation of a biologic was lower in households where other family members incurred high OOP expenses.

Conclusions. The use of biologic therapy for RA is sensitive to benefit generosity and household financial burden. The increasing use of coinsurance rates for specialty drugs (as under Medicare Part D) raises concern about adverse health consequences.

Ancillary